medigraphic.com

2021, Number 3

<< Back Next >>

Rev Cuba Endoc 2021; 32 (3)

Subclinical cardiovascular disease in relatives of women with polycystic ovary syndrome and its association with insulin resistance

Ovies CG, Hechavarría PS, Alonso DE, Hernández VD, Monteagudo PG

Language: Spanish
References: 19
Page:
PDF size: 197.61 Kb.


ABSTRACT

Introduction: Relatives of women with polycystic ovary syndrome have been show to present a higher frequency of cardiovascular risk factors, such as insulin resistance, type 2 diabetes mellitus, dyslipidemia and arterial hypertension. Therefore, these people have a higher risk for developing cardiovascular disease.
Objective: To determine the frequency of subclinical cardiovascular disease in first-degree relatives of women with and without polycystic ovary syndrome and its relationship with insulin resistance.
Methods: A cross-sectional and descriptive study was carried out with 36 first-degree relatives of women with polycystic ovary syndrome and with the same number of relatives of women without the disease. None of the members of both groups had a history of diabetes mellitus, prediabetes, dyslipidemia, high blood pressure, or obesity. To carry out the comparison of the results of the tests carried out, they were matched at a 1: 1 ratio, by age ± 5 years, relationship, sex and body mass index.
Results: There were 21 relatives with subclinical cardiovascular disease, 71.4% of which belonged to the study group, why 28.6% belonged to the control group (P < 0.05). Of the total family members of the study group, with insulin resistance, 65.0% had subclinical cardiovascular disease. In the control group, with normal fasting insulinemia, none has subclinical cardiovascular disease.
Conclusions: Subclinical cardiovascular disease is more frequent in the relatives of women with polycystic ovary syndrome, while insulin resistance is significantly associated with this condition in both groups.


REFERENCES

  1. Sam S, Coviello A, Legro R, Dunaif A. Insulin Resistence and Dyslipidemia in Brothers of Women with Polycystic Ovary Syndrome. Diabetes Care. 2008 [acceso: 06/01/2021];31:1237-41. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/18332151/

  2. Baillargeon J, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetología. 2007 [acceso: 06/01/2021];50:2424-32. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/17898989/

  3. Ovies G, Martínez A, Lardoext R, Monteagudo G. Frecuencia de componentes del síndrome metabólico en familiares de mujeres con síndrome de ovario poliquístico. Rev Cubana Endocrinol. 2017 [acceso: 06/01/2021];28:1-10. Disponible en: Disponible en: http://www.revendocrinologia.sld.cu/index.php/endocrinologia/article/view/90

  4. Yilmaz B, Priyathama Vi, Ata B, Yildiz B. Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2018 [acceso: 06/01/2021];109:356-64. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29331234/

  5. Yilmaz B, Priyathama Vi, Ata B, Yildiz B. Diabetes mellitus and insulin resistence in mothers, fathers, sisters, and brothers of women with polycyscitc ovary síndrome: a sytematic review and meta-analysis. Fertil Steril. 2018 [acceso: 06/01/2021];110:523-32. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29960703/

  6. Valdés A, Naranjo A. Enfermedad aterosclerótica subclínica. Rev Cubana Cardiol Cir Cardiovasc. 2019 [acceso: 06/01/2021];25:215-21. Disponible en: Disponible en: http://revcardiologia.sld.cu/index.php/revcardiologia/

  7. Cheang K, Nestler J, Futterweit W. Risk of Cardiovascular Events in Mothers of Women with Polycystic Ovary Syndrome. Endocr Pract. 2008 [acceso: 06/01/2021];14:1084-94. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639650/

  8. Ovies G. Agregación familiar de causa genética en el síndrome de ovario poliquístico [tesis de Maestría]. Cuba: Instituto Nacional de Endocrinología (INEN); 2014.

  9. ESHRE/ASRM-Sponsored Pcwg. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), Rotterdam. Hum Reprod. 2004 [acceso: 06/01/2021];7:41-7. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/14688154/

  10. Taylor M, Reema A, Kunselman A, Stetter C, Dunaif A, Legro R. Evidence for increased cardiovascular events in the fathers but not mothers of women with polycystic ovary syndrome. Hum Reprod. 2011 [acceso: 06/01/2021];26:2226-31. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/21505042/

  11. Louwers YV, Roest ME, Kleefstra N, Roeters van Lennep J, van den Berg M, Fauser BC, et al. Excess mortality in mothers of patients with polycystic ovary syndrome. Human Reprod. 2014 [acceso: 06/01/2021];29:1780-6. Disponible en: Disponible en: https://www.researchgate.net/publication/262787221

  12. Hunter A, Vimplis S, Sharma A, Eid N, Atiomo W. To determine whether first-degree male relatives of women with polycystic ovary syndrome are at higher risk of developing cardiovascular disease and type II diabetes mellitus. J Obstet Gynaecol. 2007 [acceso: 06/01/2021];27:591-6. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/17896258/

  13. Yilmaz M, Bukan N, Ersoy R, Karakoc A, Yetkin I, Ayvaz G, et al. Glucose intolerance, insulin resistance, and cardiovascular risk factors in first-degree relatives of women with polycystic ovary syndrome. Hum Reprod. 2005 [acceso: 06/01/2021];20:2414-20. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/15890734/

  14. Atiomo W, El-Mahdi E, Hardiman P. Family associations in women with ovarian syndrome polycystic. Fertil Steril. 2003 [acceso: 06/01/2021];80:143-5. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/12849816/

  15. Crofts C, Zinn C, Wheldon M, Grant M, Schofield G. Hiperinsulinemia (y resistencia a la insulina). Su papel en la génesis de las enfermedades cardiovasculares. Diabesity. 2015 [acceso: 06/01/2021];1:34-43. Disponible en: Disponible en: http://articulos.sld.cu/medicinainterna/archives/3747

  16. Reaven G. Insulin resistance and coronary heart disease in non-diabetic individuals. Arterioscler Thromb Vasc Biol. 2012 [acceso: 06/01/2021];32:1754-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/22815340/

  17. Vafaeimanesh J, Parham M, Norouzi S, Hamednasimi P, Bagherzadeh M. Insulin resistance and coronary heart disease in non-diabetic patients: is there a correlation?. Caspian J Intern Med. 2018 [acceso: 06/01/2021];9:121-6. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/29732028/

  18. Hyderali B, Mala K. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. Europ J Obst Gynecol Reprod Biol. 2015 [acceso: 06/01/2021];191:15-22. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26066290/

  19. Targher G, Zoppini G, Bonora E, Moghetti P. Hemostatic and fibrinolytic abnormalities in polycystic ovary syndrome. Semin Thromb Hemost. 2014 [acceso: 06/01/2021];40:600-18. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/25000958/




2020     |     www.medigraphic.com